Dialog Box

CheckMate 743 presented at ESMO confirms the role of immunotherapy in first-line mesothelioma

In the phase III CheckMate 743 study, the 3-year overall survival rate for nivolumab plus ipilimumab was 1.5-times that of chemotherapy in patients with unresectable malignant pleural mesothelioma.

Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years: the 3-year duration-of-response rate was 28% among patients receiving immunotherapy but 0% in those receiving chemotherapy.

Learn more

Learn more about what happened at ESMO or refer a patient with unresectable malignant pleural mesothelioma.

ESMO WebsiteRefer a Patient

14 October 2021
Category: News